RESUMO -O eritema anular centrífugo. é uma dermatose de etiologia desconhecida e geralmente auto-limitada. Apesar disto, alguns casos tendem para a cronicidade, especialmente quando não é identificado o estímulo causal. Estes últimos casos são geralmente desafiantes do ponto de vista terapêutico. Um homem de 24 anos recorreu à consulta de Dermatologia por placas policíclicas múltiplas, com crescimento radial, bordo infiltrado e clareamento central, localizadas nos glúteos, antebraços e coxas com 3 anos de evolução. A correlação clinico-patológica conduziu ao diagnóstico de eritema anular centrifugo. Foram excluídas causas secundárias. O tratamento com corticoides tópicos e sistémicos não ofereceu qualquer melhoria, e o doente estava relutante em tentar imunossupressores sistémicos orais. Optou-se assim pela fotoquimioterapia. Uma melhoria muito significativa foi verificada desde o primeiro tratamento, ficando o doente completamente limpo ao sétimo tratamento. Aos 3 meses de follow-up, mantem-se em remissão. No nosso conhecimento, relatamos o primeiro caso de eritema anular centrífugo tratado de forma bem-sucedida com fotoquimioterapia. Enfatizamos o papel que esta modalidade terapêutica clássica ainda pode, e deve ocupar no tratamento de dermatoses inflamatórias refratárias, como o eritema anular centrífugo. PALAVRAS-CHAVE -Eritema/tratamento; Fotoquimioterapia. 
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INTRODUCTION
Erythema annulare centrifugum (EAC) is a figurate erythema which represents a delayed hypersensitivity reaction.
1,2 In many cases the offending insult cannot be found and eliminated, leading to a chronic course for which effective therapies are lacking. Herein, we describe the complete resolution of a recalcitrant EAC using photochemotherapy, a long-established treatment in the dermatological armamentarium, yet unexplored for this purpose.
CASE REPORT
A 24-year-old, skin type III Caucasian male presented with a 3-year history of persistent, mildly pruritic plaques with polycyclic outlines and an infiltrated rim on the forearms, buttocks and thighs (Fig. 1A,1C,1E ). The lesions began as small papules which expanded centrifugally through a leading edge, many of them with a trailing scale. Patient's medical past and general physical exam were unremarkable. Regular or sporadic use of medications was denied. A skin biopsy showed perivascular and periadnexal lymphocytic infiltrates with an acanthotic epidermis, parakeratosis, pitiriasiform vesiculation and scant spongiosis (Fig. 2) . Clinicopathological correlation established a diagnosis of EAC. An extensive laboratorial (blood cell count and differential, routine biochemistry, serum electrophoresis, protein count, viral serologies, erythrocyte sedimentation rate, thyroid panel, ANA and rheumatoid factor, stool tests for bacterial, viral and parasitic pathogens, interferon gamma release assay for tuberculosis) revealed no abnormalities. Further investigation, including mycological and imaging tests were also unremarkable. Topical and systemic steroids were tried for a full year with little success and ensuing immediate relapses. Doxycycline 200 mg/daily provided mild benefit. The patient was reluctant to try oral or injectable immunomodulators. Treatment with psoralen ultraviolet-A (PUVA) twice weekly was then attempted (initial/final dose: 2.0/8.0J cm 2 , respectively). A major improvement was progressively observed to a complete response on the 7 th session (Fig. 1B,1D ,1F). No side effects were observed. The patient was utterly satisfied. PUVA was stopped after the 20 th treatment and no relapses have so far been observed on short follow-up (six months).
DISCUSSION
In many cases, EAC follows a self-limiting course. In others, a culprit stimulus can be found, either an infection, a drug, an underlying malignancy or any other disorder from a wide spectrum of putative associations. 2 Addressing the noxious stimuli usually leads to remission and hence is the therapy cornerstone. Albeit the apparent favourable prognosis, there is a subset of patients who follow a chronic, debilitating course for which symptomatic treatment is desired. Topical and systemic steroids are widely used, but long-term risks and relapses following discontinuation 
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A B C D demand steroid-sparing therapeutic options. Consensus treatment guidelines are unfortunately inexistent for recalcitrant cases. Systemic immunomodulators are often given but may fail to provide relief. 3 Erythromycin was reported as temporarily effective, 1 while a case documented a complete response with oral metronidazole 4 and another case reported full remission with oral doxycycline therapy. 5 Etanercept 25 mg biweekly induced complete clearance over a 6-month period in one patient. 2 Phototherapy is a time-honoured therapeutic modality in many dermatological conditions, 6 but evidence for its application in EAC is scarce. Narrow-band ultraviolet--B combined with calcipotriol ointment for 4-weeks led to remission in one case. 7 Natural sunlight led to clearance in 2 cases. 8 To our knowledge, this is the first report of a refractory, debilitating EAC case successfully managed with PUVA. A Th1-mediated pathogenesis has been speculated, in which tumour necrosis factor alfa (TNF-α) and associated cytokines play a critical role. 2 Indeed, inflammatory dermatoses are successfully treated by phototherapy through an interplay of photobiologic mechanisms, 6 such as the down-regulating an overreactive, dysregulated Th1/Th17 axis and its orchestrated inflammatory cascade, including TNF-α.
We opted for photochemotherapy as, for this condition, it might be more effective than NB-UVB. Moreover, the twice-weekly PUVA regimen suited better the patient's busy schedule than its thrice-weekly NB-UVB, which reflected in a high-adherence rate. EAC histopathology often reveals dermal lymphocytic infiltrates, especially on its deep variant. 9 Ultraviolet-A irradiation allows for deeper, mid-to deep-dermal immunomodulation 10 which may superiorly target these immune cells. Furthermore, photochemotherapy leads to faster and longer lasting remission in other inflammatory cutaneous diseases. 11 Nevertheless, an unfavourable response to PUVA was previously reported in an isolated report, 12 albeit decisive therapeutic variables such as treatment adherence and dose regimen were not included in the report. In summary, the rapid resolution, excellent tolerability and sustained response makes PUVA an encouraging treatment for EAC. Despite a single report, we believe photochemotherapy should be further explored to ascertain the efficacy and long-term clearance rates of EAC with this promising and dermatologic-specific approach. 
